Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients
Status:
Withdrawn
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
Hypothesis 1: Treatment of heart transplant recipients with sildenafil, a PDE-5 inhibitor,
will improve small artery elasticity (SAE) when compared to placebo.
Hypothesis 2: PDE-5 inhibition will improve endothelial function, resulting in increased
production of nitric oxide, reduced activation of circulating endothelial cells, and
increased endothelial progenitor cells.
Phase:
N/A
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute